(F19) From A1C to FIB-4: Practical Guidance on MASLD and MASH for the DCES

Metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction–associated steatohepatitis (MASH), are highly prevalent yet under-recognized comorbidities in people with T2D. Despite strong associations with insulin resistance, cardiovascular disease, and adverse liver-related outcomes, routine identification and management remain inconsistent in clinical practice. This session will provide diabetes care and education specialists with a practical framework to identify MASLD and MASH using readily available clinical data, understand appropriate risk stratification strategies, and apply evidence-based lifestyle and pharmacologic interventions. Emphasis will be placed on integrating liver health into diabetes workflows, clarifying the role of emerging therapies, and supporting interdisciplinary care to improve cardiometabolic outcomes.